



National Comprehensive
Cancer Network®

NCCN Global Academy for Excellence & Leadership in Oncology™



School of Pharmaceutical & Biotech Business

Tuesday, 12 November 2024



National Comprehensive
Cancer Network®

NCCN Global Academy for Excellence & Leadership in Oncology™ School of Pharmaceutical & Biotech Business

Live Virtual Event
Tuesday, 12 November 2024
9:00 AM – 12 PM EST

9:00 – 9:05 AM

Introduction

Moderator

Clifford Goodman, PhD

Consultant, Health Care Technology and Policy

9:05 – 10:15 AM

Module I: Adaptation and Implementation of NCCN Guidelines Outside the US: Opportunities and Challenges

Kanaan Alshammari, MBChB

Consultant Medical Oncologist

Ministry of National Guard Health Affairs

Riyadh, Saudi Arabia

Karine Trindade, MD

Medical Oncologist

Latin American Cooperative Oncology Group (LACOG)

Nomsa Tsikai, MBChB, MMed Rad-Onc

Chief Oncologist

Harare Oncology Centre in Zimbabwe

Piotr Rutkowski, MD, PhD

*Professor, Head of Department of Soft Tissue/Bone Sarcoma and
Melanoma, Plenipotentiary of Head Director for National Oncological
Strategy and Clinical Trials, President of Polish Oncological Society
Maria Skłodowska-Curie National Research Institute of Oncology
Warsaw, Poland*

Tran Thanh Huong, MD, PhD

Vice Director

Vietnam National Cancer Hospital



10:15 – 10:30 AM

Break

10:30 – 11:45 AM

**Module II: The Role of Health Technology Assessment (HTA) and
other Value Considerations**

Chris Sampson, PhD

Senior Principal Economist
Office of Health Economics (OHE)

Marjorie Morrison, MHA

Director, Policy & Advocacy
Lymphoma Coalition

Paulette Ibeka, MPH

PhD Candidate
University of Toronto
Previously at Clinton Health Access Initiative Inc., Nigeria

Tit Albreht, MD, PhD

Head of the Centre, Senior Researcher
National Institute of Public Health of Slovenia

Tit Albreht, MD, PhD




Prof. Tit Albreht, M.D., Ph.D. in Health Services Research at the University of Amsterdam, Head of the Centre for Health Care at the National Institute of Public Health of Slovenia, Senior Researcher in the field of health services research, health policy and health systems research, member of the Scientific Committee of EUPHA. He served as President of the Slovenian Preventive Medicine Society between 2016 and 2022 and was elected President-elect of the European Public Health Association for the term 2024-2026. His research and policy work has predominantly been on national and EU policies in health workforce, patient mobility, cancer control and cancer care (the latter two since 2006). He was the scientific coordinator of four EU cancer policy projects, Joint Actions. He is assistant professor of public health at both Slovenian medical faculties as well as at the Faculties of Nursing in Maribor and Jesenice. He has more than 50 scientific publications in PubMed and an h.index in WoS and Scopus of 10.

Kanaan Alshammari, MBChb



Dr. Kanaan Alshammari is a consultant of adult medical oncology at King Abdulaziz Medical City – Ministry of National Guard for Health Affairs (MNGHA) in Riyadh, Saudi Arabia, and an Assistant Professor at the College of Medicine of King Saud bin Abdulaziz University (KSAU) for Health Sciences. He is also the director of the NCCN MENA regional coordinating center at MNGHA. He finished his undergraduate training at the University of Otago in New Zealand obtaining his MBChB in 2008. He then obtained the Saudi Board of Internal Medicine in 2014. He did his medical oncology training at McMaster University in Hamilton, Canada, and obtained the Royal College of Physicians and Surgeons of Canada Subspecialty Affiliate certification in 2018. He then did another fellowship in drug development/phase 1 oncology trials and sarcoma in 2019 at the Princess Margaret Cancer Center in Toronto, Canada. He published in the areas of HCC, precision oncology, and has a great interest in sarcoma.

Tran Thanh Huong, MD, PhD



Dr. Tran Thanh Huong is the Head of the Department of Ethics and Medical Psychology, Hanoi Medical University; Vice Director of the National Institute for Cancer Control (Viet Nam National Cancer Institute); and Director of the Bright Future Foundation – Supportive Fund for Cancer Patients. She served as coordinator for the development of the National Cancer Control Program and Cancer Registry in Vietnam. She also led the National Survey on NCD Risk Factors (STEPS) in eight different regions in Vietnam, and conducted pilot studies on intervention models for diabetes, hypertension and other NCD types. Dr. Huong’s research areas focused on identifying risk factors of non-communicable diseases (NCDs), which includes cancer (epidemiology, risk factors, feasibility of cancer screening models in low-resource settings), mental health, CVD, and diabetes. She is also interested in cancer control & outcome research with a goal of setting up intervention for improved quality of life for cancer patients. Dr. Huong’s most interested intervention is psychosocial in cancer patients.

Together with Dr. Xiao-Ou Shu from Vanderbilt University Medical Center, Dr. Huong led the effort, funded by NIH (P20 CA210300), “Regional Center for Research Excellence in Non-communicable Disease Epidemiology and Prevention in Vietnam.” She has coordinated the program “Breast Cancer Prevention” and project “Advancing cancer control in Vietnam: selection of appropriate technique for breast and cervical cancer in low-middle income countries,” as well as served as PI or co-PI for several studies. Most recently, she is the multi-PI of the “Vanderbilt-Vietnam Genetic Epidemiology Training Program (V2-GENE)” which is an initiative to train scholars in the genetic epidemiology of noncommunicable diseases. Dr. Huong has published more than 110 peer-reviewed papers in National and International journals and has mentored more than 40 undergraduate and graduate students.

Paulette Ibeka, MPH



Paulette Ibeka is a distinguished health systems strategist and policy expert with over a decade of transformative experience across Sub-Saharan Africa. As a Senior Program Manager at Clinton Health Access Initiative Inc. (CHAI) in Nigeria, she spearheaded groundbreaking initiatives in Non-Communicable Diseases (NCDs) and Access to Assistive Technology and Sexual Reproductive, Maternal, Neonatal, Child Health, and Nutrition (RMNCH+N). Through her leadership, Nigeria launched the first ever pooled procurement program that has grown from 6 to 22 hospitals that support access to stringent regulatory authority (SRA)-approved anticancer medicines at more than 50% price reduction for over 5800 cancer patients. The program’s combination of quality and price transparency has led to government financing that supports treatment for patients with the three most prevalent cancers—breast, prostate, and cervical cancers.

Ms. Ibeka’s expertise lies in providing high-level technical guidance to federal and regional governments, fostering innovative public-private partnerships, and leveraging data-driven technologies to enhance access to quality healthcare in low and middle-income countries (LMICs).

Her strategic approach has been instrumental in mobilizing resources and forging collaborations with global entities such as the City Cancer Challenge and St. Jude's Global Alliance.

A key achievement in Ms. Ibeka's career has been her pivotal role in establishing partnerships between the Nigerian Government and pharmaceutical giants, including Pfizer, Roche, and Janssen. This has significantly advanced cancer control efforts in the region. Her work has not only improved access to essential medications but also contributed to shaping national health policies and guidelines, instilling a sense of hope and optimism in her audience.

As a researcher, Ms. Ibeka has been at the forefront of designing and implementing critical studies that generate evidence to inform policymaking and drive practice change. Her contributions have been particularly impactful in cancer care, hypertension management, and assistive technology access.

Currently pursuing her Ph.D. at the prestigious University of Toronto, Ms. Ibeka brings a robust academic background to her practical experience. She holds a Master's in Public Health from the City University of New York (CUNY), Hunter, and an Advanced Certificate in Health Care Management from the State University of New York at Stony Brook.

Ms. Ibeka's unique blend of strategic thinking, policy expertise, and on-ground experience navigating complex health systems makes her a valuable voice in global health discussions, particularly in addressing the challenges faced by low—and middle-income countries in achieving universal health coverage and sustainable development goals.

Marjorie Morrison, MHA



Marjorie Morrison is the Director of Policy and Advocacy with Lymphoma Coalition where she leads global projects related to health technology assessment.

Marjorie has an extensive history working in patient advocacy and policy in the cancer care landscape. Before joining Lymphoma Coalition, she served in a senior leadership capacity for ten years where she led a pan-Canadian network of health associations and patient organisations to accelerate the implementation of Canada's national cancer strategy and embed patient perspectives across the cancer control continuum. More recently, her role with the Canadian Association for Population Therapeutics focused on advancing population-based research of therapeutic interventions to improve patient outcomes. Marjorie is passionate

about health systems and policy interventions and is deeply committed to ensuring patient experience and evidence-based data help to inform patient care, access, and treatment. In her role with Lymphoma Coalition, Marjorie currently chairs a global HTA Special Interest Group comprised of patient organisations involved in HTA processes and coordinates the involvement of appointed organisational patient advocates serving on the European Commission HTA Stakeholder Network. Marjorie also leads organisational contributions to the European Commission public consultations on HTA in Europe and represents Lymphoma Coalition with external HTA-related partners and various global interest groups. An outdoor enthusiast, Marjorie is based in Canada and holds a Master of Health Administration and Master's Certificate in Health Systems Management from the University of Regina, Saskatchewan.



Piotr Rutkowski, MD, PhD



Piotr Rutkowski is Professor of Surgical Oncology at the Maria Skłodowska-Curie National Research Institute of Oncology in Warsaw, Poland.

Dr. Rutkowski is the current Head of the Department of Soft Tissue/Bone Sarcoma and Melanoma, the Plenipotentiary of Head Director of Institute for National Oncological Strategy and Clinical Trials at the Maria Skłodowska-Curie National Research Institute of Oncology. He has participated in several investigator-driven trials in melanoma and sarcoma. He is a reviewer for several international scientific journals, as well as a member of the Editorial Board of Annals of Surgical Oncology and European Journal of Surgical Oncology.

Dr. Rutkowski is an active member of the EORTC Melanoma Group; EORTC Soft Tissue and Bone Sarcoma Group, where he chaired the Local Treatment Subcommittee and the Membership Committee of the EORTC Board. He is a member of several Polish and international scientific societies (President of Polish Oncological Society, Board member of Polish Society Surgical Oncology, Ex-member of the Board of Directors of the Connective Tissue Oncology Society, member of Membership Advisory Committee of ASCO, Global Curriculum Committee of ESMO). Prof. Rutkowski has authored or co-authored over 500 scientific papers in Polish and international journals (with an impact factor of above 4000, index-H:80, citation index >30000, rewarded Highly Cited Researcher in Clinical Medicine 2021, 2022, 2023 and 2024), and is co-author of national and international recommendations for sarcoma and melanoma. He is working very closely with national patient advocacy groups for GIST/sarcoma and melanoma, coordinating Polish Sarcoma Group and is Chairman of the Melanoma Academy in Poland. President of Council of Agency of Medical Research. Chair of Task Group of Ministry of Health, Poland for National Oncological Strategy.

Chris Sampson, PhD



Chris Sampson, PhD, is a Senior Principal Economist at the Office of Health Economics (OHE), where he is the research theme lead for Value, Affordability, and Decision Making. His research has contributed to the development and implementation of innovative methods for assessing the value of health care technologies, with a focus on practical applications in policy and decision-making. Chris has recently led research addressing key policy challenges in oncology, including expanding access to genomic testing and devising new approaches to the pricing of combination therapies.

Karine Trindade, MD

Credentials include:

Medical Oncologist, Medical Manager and Research Investigator at Rede D'Or in Fortaleza, CE, Brazil

Chair of Latin American Cooperative Oncology Group (LACOG) | Genitourinary Cancer Group

Post-graduate in Clinical Research at Harvard Medical School - Global Clinical Scholars Research Training Program

Member of the Genitourinary Tumors Committee at SBOC – Brazilian Society Clinical Oncology

Member of ASCO – American Society of Clinical Oncology

Member of ESMO – European Society of Medical Oncology

Nomsa Tsikai, MBChb, MMed Rad-Onc

Nomsa Tsikai is a passionate Clinical Oncologist with 13 years of experience in cancer management. She has specialized in Radiotherapy and Oncology and is committed to delivering extraordinary patient-centered care. Nomsa is the lead oncologist at the Harare Oncology Centre which is a professional and efficient cancer treatment centre in Harare.

Upcoming Events

View the online calendar at [NCCN.org/events](https://www.nccn.org/events).

Save the Date! Thursday, March 27, 2025
New location! Caribe Royale Orlando, Orlando, FL



**NCCN Academy for Excellence
& Leadership in Oncology™**

School of Pharmaceutical & Biotech Business

[NCCN.org/academy](https://www.nccn.org/academy)



Register Now



**Annual 2025
Conference**



Friday, March 28 – Sunday, March 30, 2025

New Location! Caribe Royale Orlando • Orlando, FL

[NCCN.org/conference](https://www.nccn.org/conference)

Pre-Conference Program

NCCN 2025 Nursing Program: Advancing Oncology Nursing™

Thursday, March 27, 2025